Paper42394820
Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC and 3 others. Front Cell Infect Microbiol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Papers, record 42394820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42394820
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pyridines | Major topic |
| Triazoles | Major topic |
| Antifungal Agents | Major topic |
| Aspergillus | Major topic |
| Aspergillosis | Major topic |
| Serum Albumin | Major topic |
| Nitriles | Major topic |
| Humans | |
| Monte Carlo Method | |
| Microbial Sensitivity Tests | |
| Adult | |
| Hypoalbuminemia | |
| Immunocompromised Host | |
| Female | |
| Middle Aged |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40153171 | An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of Indications, Exposure and Hepatic Safety. | Clin Drug Investig | 2025 | https://conductscience.org/library/papers/40153171 | PubMed |
| 2 | 25753636 | Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25753636 | PubMed |
| 3 | 28803138 | Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. | Am J Med | 2017 | https://conductscience.org/library/papers/28803138 | PubMed |
| 4 | 26598096 | Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. | Pharmacotherapy | 2015 | https://conductscience.org/library/papers/26598096 | PubMed |
| 5 | 35191210 | Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects. | Clin Pharmacol Drug Dev | 2022 | https://conductscience.org/library/papers/35191210 | PubMed |
| 6 | 25624327 | Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25624327 | PubMed |
| 7 | 31119272 | Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31119272 | PubMed |
| 8 | 39540734 | Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/39540734 | PubMed |
| 9 | 33782547 | High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/33782547 | PubMed |
| 10 | 40490059 | Population pharmacokinetics of isavuconazole in hematologic patients: implications for model-informed precision dosing. | Eur J Pharm Sci | 2025 | https://conductscience.org/library/papers/40490059 | PubMed |
| 11 | 39138063 | A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole. | Med Mycol | 2024 | https://conductscience.org/library/papers/39138063 | PubMed |
| 12 | 26000646 | Isavuconazole: a new extended spectrum triazole for invasive mold diseases. | Future Microbiol | 2015 | https://conductscience.org/library/papers/26000646 | PubMed |
| 13 | 38436619 | Pharmacological management of invasive mold infections in solid organ transplant recipients. | Expert Opin Pharmacother | 2024 | https://conductscience.org/library/papers/38436619 | PubMed |
| 14 | 28702763 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. | Infection | 2017 | https://conductscience.org/library/papers/28702763 | PubMed |
| 15 | 32721598 | Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/32721598 | PubMed |
| 16 | 40240233 | Pharmacokinetic novelties of isavuconazole. Use in special situations. | Rev Iberoam Micol | 2025 | https://conductscience.org/library/papers/40240233 | PubMed |
| 17 | 39200006 | Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39200006 | PubMed |
| 18 | 34188199 | Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019). | J Antibiot (Tokyo) | 2021 | https://conductscience.org/library/papers/34188199 | PubMed |
| 19 | 36781411 | Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses. | J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/36781411 | PubMed |
| 20 | 40566598 | Optimization of Isavuconazole Dosing in Patients with Invasive Fungal Infections Through Therapeutic Drug Monitoring: Real-World Clinical Practice Experience. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40566598 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42394820
GET https://conductscience.org/api/papers/v1/42394820/references?page=2